Renasight Genetic Testing | Natera

Renasight

Discover what genes have to say about kidney health

Renasight is a test to determine if there is a genetic cause for an individual’s kidney disease or if there is increased risk due to family history.

Tests For:

382 genes associated with kidney disease

Collection Sample:

Blood, Saliva

Turn Around Time:

~3 weeks

Renasight provides valuable information for disease management.

Benefits of genetic testing


Insight

into progression of CKD

Identify

the underlying cause for CKD of unknown origin

Target

therapies for personalized treatment

Test

family members for risk of disease


Interested in learning more about Renasight?

Learn more


Why choose Renasight?

 

Comprehensive


  • Leverages next generation sequencing to analyze over 380 genes that were hand selected by genetic experts to provide actionable information.

  • Test covers both common inherited disorders and less frequent disorders associated with kidney disease.


Convenient


  • Remote testing services including virtual ordering for providers and at home sample collection options for patients (saliva or mobile blood draw).

  • Complimentary information sessions with board-certified genetic counselors.

 


 

Accessible


  • All insurance plans accepted and affordable testing options available through a variety of payment methods.


How to get started

1

Provider orders the Renasight test.

2

Patient provides a blood or saliva sample.
Remote collection services available.

3

Results are available for review in about 3 weeks.

Request information to get started

or contact renasight@natera.com to request a collection kit


American adults at risk for chronic kidney disease1

1 in 3
Patients with CKD who have a genetic diagnosis2

~1 in 10
Patients with CKD whose genetic diagnosis led to changes in clinical management2
89%

Request more information about Renasight

 


References

  1. Kidney Disease: The Basics. National Kidney Foundation.
  2. Groopman EE, Marasa M, Cameron-Christie S et al. Diagnostic utility of exome sequencing for kidney disease. NEJM. 2018;doi:10.1056.

The test described has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA is exercising enforcement discretion of premarket review and other FDA legal requirements for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. CAP accredited, ISO 13485 certified, and CLIA certified. © 2020 Natera, Inc. All Rights Reserved.